- Home
- ZLAB vs PTGX Comparison
ZLAB vs PTGX Comparison
Compare ZLAB & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 5.4B |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | PTGX |
|---|---|---|
| Price | $17.64 | $87.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $57.22 | ★ $90.56 |
| AVG Volume (30 Days) | 828.8K | ★ 930.4K |
| Earning Date | 11-06-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $441,629,000.00 | $209,217,000.00 |
| Revenue This Year | $26.16 | N/A |
| Revenue Next Year | $30.62 | $288.98 |
| P/E Ratio | ★ N/A | $121.27 |
| Revenue Growth | ★ 24.14 | N/A |
| 52 Week Low | $16.82 | $33.70 |
| 52 Week High | $44.34 | $96.54 |
Technical Indicators
Market Signals| Indicator | ZLAB | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 49.63 |
| Support Level | $17.50 | $84.11 |
| Resistance Level | $17.97 | $89.61 |
| Average True Range (ATR) | 0.62 | 2.97 |
| MACD | 0.26 | -0.69 |
| Stochastic Oscillator | 37.90 | 25.58 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.